Gilead Sciences (GILD) to Release Earnings on Wednesday

Gilead Sciences (NASDAQ:GILD) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Gilead Sciences to post earnings of $1.66 per share for the quarter. Gilead Sciences has set its FY24 guidance at $3.60-3.90 EPS and its FY 2024 guidance at 3.600-3.900 EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, analysts expect Gilead Sciences to post $4 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Gilead Sciences Stock Up 0.8 %

Shares of NASDAQ GILD opened at $89.51 on Monday. The company has a 50 day simple moving average of $83.79 and a 200 day simple moving average of $74.21. The firm has a market cap of $111.44 billion, a PE ratio of 109.16, a price-to-earnings-growth ratio of 3.09 and a beta of 0.17. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $89.74. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GILD. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Wells Fargo & Company raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $78.00 to $100.00 in a research report on Monday, October 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price objective on shares of Gilead Sciences in a report on Tuesday, October 29th. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 9th. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $86.85.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.